Lipella Pharmaceuticals Inc. Investing Cash Flow
Lipella Pharmaceuticals Inc. (LIPO) reported Investing Cash Flow of -$14.43 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-28.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2025-03-28
- Lipella Pharmaceuticals Inc. net cash provided by (used in) investing activities for the quarter ending 2023-12-31 was $0.00.
- Lipella Pharmaceuticals Inc. net cash provided by (used in) investing activities for the quarter ending 2022-12-31 was $0.00.
- Lipella Pharmaceuticals Inc. net cash provided by (used in) investing activities for the quarter ending 2022-09-30 was $0.00.
- Lipella Pharmaceuticals Inc. net cash provided by (used in) investing activities for the quarter ending 2022-06-30 was $600.54K.
- Lipella Pharmaceuticals Inc. net cash provided by (used in) investing activities for fiscal 2023 was -$14.43K, a 104.80% decline from fiscal 2022.
- Lipella Pharmaceuticals Inc. net cash provided by (used in) investing activities for fiscal 2022 was $300.55K.
- Lipella Pharmaceuticals Inc. net cash provided by (used in) investing activities for fiscal 2021 was -$300.55K.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | -$14.43K 10-K · filed 2025-03-28 | ||
| 2023-09-30 | -$14.43K 10-Q · filed 2024-11-14 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $0.00 derived: sum of 2 quarters · filed 2024-02-27 | $600.54K derived: sum of 3 quarters · filed 2024-02-27 | $300.55K 10-K · filed 2024-02-27 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $600.54K derived: sum of 2 quarters · filed 2023-11-14 | $300.55K 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $600.54K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $300.55K 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | -$300.00K 10-Q · filed 2023-05-12 | |||
| 2021-12-31 | -$300.55K 10-K · filed 2023-03-31 |